Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label attachment file name title previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1140520

	registered interest
	date	19/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Fish: Hygiene and Safety
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether the safety and food hygiene rules for the transport of smoked fish (a) within and (b) to the UK is governed by (i) UK or (ii) EU regulations.
	tabling member constituency	Cardiff Central
	tabling member printed	Jo Stevens
	uin	279407
	answer	answer is ministerial correction date of answer 26/07/2019 answer text <p>The longstanding rules governing the transport of food of animal origin, including smoked fish are provided by European Union food safety and hygiene regulations which apply directly to the United Kingdom. This legislation lays down effective and proportionate food safety and hygiene controls throughout the food chain, from primary production to sale or supply to the food consumer. In England, The Food Safety and Hygiene (England) Regulations 2013 provides for the enforcement of certain provisions of EU food safety hygiene legislation. It also provides national law for certain elements including temperature control in retail establishments. Parallel legislation applies in Scotland, Wales and Northern Ireland.</p><p> </p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 26/07/2019 11:42:59 answering member 4455 label Biography information for Seema Kennedy previous answer version 131082 answering member constituency South Ribble answering member printed Seema Kennedy answering member 4455 label Biography information for Seema Kennedy
	tabling member	4425 label Biography information for Jo Stevens

1137874

	registered interest
	date	09/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Phenylketonuria: Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the extent of regional disparities in support for people with Phenylketonuria.
	tabling member constituency	Cardiff Central
	tabling member printed	Jo Stevens
	uin	275229
	answer	answer is ministerial correction date of answer 15/07/2019 answer text <p>In England, services for patients with Phenylketonuria are provided via two routes, nationally commissioned through the National Health Service and through local clinical commissioning groups (CCGs), for example for food supplements.</p><p>The Government and the NHS are dedicated to offering a consistent approach to treatment and provide the best local care for patients with both, rare and common diseases. Services commissioned locally through CCGs via sustainability and transformation partnerships (STPs) enable service coordination across wider footprints. In England, the NHS Long Term Plan set out the ambition for all STPs to evolve into integrated care systems (ICSs) by April 2021. ICSs are an ‘evolved’ form of a STP, making faster progress in integrating care across their area, bringing together organisations to provide more seamless care for patients<strong>. </strong></p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 15/07/2019 16:32:34 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4425 label Biography information for Jo Stevens

1137621

	registered interest
	date	08/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Soft Drinks: Taxation
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the (a) amount of revenue raised and (b) effect on public health of the Soft Drinks Industry Levy.
	tabling member constituency	Cardiff Central
	tabling member printed	Jo Stevens
	uin	274567
	answer	answer is ministerial correction date of answer 11/07/2019 answer text <p>Her Majesty's Revenue and Customs (HMRC) has records of the amount of revenue raised through the Soft Drinks Industry Levy (SDIL).</p><p>The SDIL was introduced in April 2018 with money to the public purse accruing from this date. Monthly and annual receipts from SDIL are published in HMRC’s National Statistics publication, which can be accessed via the following link:</p><p><a href="https://www.gov.uk/government/statistics/hmrc-tax-and-nics-receipts-for-the-uk" target="_blank">https://www.gov.uk/government/statistics/hmrc-tax-and-nics-receipts-for-the-uk</a></p><p>Public Health England has not made an assessment of the effect of the SDIL on public health. The National Diet and Nutrition Survey is used to monitor trends in consumption of sugary soft drinks and in sugar intakes. Data covering the period when the SDIL was introduced will become available in 2020. However, the survey cannot attribute changes in consumption to individual policies.</p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 11/07/2019 13:23:44 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4425 label Biography information for Jo Stevens

1125633

	registered interest
	date	09/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	General Practitioners
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment his Department has made of trends in the number of GPs per 100,000 people in England since 2010.
	tabling member constituency	Cardiff Central
	tabling member printed	Jo Stevens
	uin	252606
	answer	answer is ministerial correction date of answer 14/05/2019 answer text <p>The number of general practitioners (GPs) and clinical staff per 100,000 registered patients is available in the table attached for the years 2015-18 (headcount and full-time-equivalent (FTE)). Data is not included prior to 2015. GP locums are excluded as improvements have been made to GP locum recording methodology and figures are not comparable prior to December 2017.</p><p> </p><p>The recently published NHS Long Term Plan made a clear commitment to the future of general practice, with primary and community care set to receive at least £4.5 billion more in real terms a year by 2023/24, meaning spending on these services will grow faster than the rising NHS budget. Since the launch of the Long Term Plan, NHS England and the British Medical Association’s General Practitioners Committee have agreed a five-year GP (General Medical Services) contract framework from 2019/20. The new contract framework will be essential to deliver the ambitions set out in the NHS Long Term Plan through strong general practice services.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 14/05/2019 15:19:18 answering member 4455 label Biography information for Seema Kennedy attachment 1 file name PQ252606 Annex 1 GPs per 100000 patients table formatted.docx title Regular GP Table
	tabling member	4425 label Biography information for Jo Stevens

1124982

	registered interest
	date	07/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 24 April 2019 to Question 244142 on Cannabis: Medical Treatments, whether his Department defines Naboline as a cannabis imitating rather than cannabis derived product.
	tabling member constituency	Cardiff Central
	tabling member printed	Jo Stevens
	uin	251364
	answer	answer is ministerial correction date of answer 13/05/2019 answer text <p>The Department recognises both Nabilone and Sativex as licensed cannabis-based medicines. Neither, however, falls within the scope of the definition of a ‘cannabis-based product for medicinal use’ under the recent change to the law.</p><p>Nabilone is a synthetic non-natural cannabinoid that mimics delta-9-tetrahydrocannabinol (THC). It was issued a marketing authorisation by the Medicines and Healthcare products Regulatory Agency (MHRA), for nausea and vomiting caused by chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments, on 14 February 1995. There are no restrictions on its prescribing in the National Health Service.</p><p>Sativex (nabiximols) is an oromucosal spray that contains THC and cannabidiol (CBD). It was issued a marketing authorisation by the MHRA, for treatment of spasticity in people with multiple sclerosis who have failed to respond adequately to other anti-spasticity medications, on 16 June 2010. In October 2014, the National Institute for Health and Care Excellence recommended that Sativex is not offered for use on the NHS because it is not a cost-effective treatment. Sativex therefore is not routinely prescribed on the NHS, and can only be prescribed for an individual patient, where local governance and funding arrangements allow for this.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 251366 question first answered 13/05/2019 15:38:24 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4425 label Biography information for Jo Stevens

1124983

	registered interest
	date	07/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 24 April 2019 to Question 244142 on Cannabis: Medical Treatments, whether his Department is aware of any instances of (a) CBD and (b) THC being prescribed by the NHS since 1 January 2019.
	tabling member constituency	Cardiff Central
	tabling member printed	Jo Stevens
	uin	251365
	answer	answer is ministerial correction date of answer 13/05/2019 answer text <p>The published data shows that the following number of items of Nabilone (a synthetic product which mimics tetrahydrocannabinol (THC)) and Sativex (a product containing natural THC and cannabidiol (CBD)) were dispensed in January and February 2019.</p><p> </p><table><tbody><tr><td><p> </p></td><td colspan="2"><p>Number of prescription items</p></td></tr><tr><td><p> </p></td><td><p>January 2019</p></td><td><p>February 2019</p></td></tr><tr><td><p>Nabilone</p></td><td><p>44</p></td><td><p>36</p></td></tr><tr><td><p>Sativex</p></td><td><p>167</p></td><td><p>159</p></td></tr></tbody></table><p> </p><p>Data, from the NHS Business Services Authority for January and February 2019, suggest that three National Health Service prescriptions were dispensed for unlicensed cannabis-based products for medicinal use in primary care in England during this time. Additionally, the NHS Business Services Authority data report that 10 private prescriptions were dispensed for unlicensed cannabis-based products for medicinal use in January and February 2019.</p><p> </p><p>Unlike NHS primary care where all dispensed prescriptions are processed centrally, this is not the case for secondary care. This information is collected by a third party and not routinely published.</p><p> </p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 13/05/2019 16:07:00 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4425 label Biography information for Jo Stevens

1124984

	registered interest
	date	07/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 24 April 2019 to Question 244142 on Cannabis: Medical Treatments, when (a) Naboline and (b) Savitex were first made available to prescribe on the NHS.
	tabling member constituency	Cardiff Central
	tabling member printed	Jo Stevens
	uin	251366
	answer	answer is ministerial correction date of answer 13/05/2019 answer text <p>The Department recognises both Nabilone and Sativex as licensed cannabis-based medicines. Neither, however, falls within the scope of the definition of a ‘cannabis-based product for medicinal use’ under the recent change to the law.</p><p>Nabilone is a synthetic non-natural cannabinoid that mimics delta-9-tetrahydrocannabinol (THC). It was issued a marketing authorisation by the Medicines and Healthcare products Regulatory Agency (MHRA), for nausea and vomiting caused by chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments, on 14 February 1995. There are no restrictions on its prescribing in the National Health Service.</p><p>Sativex (nabiximols) is an oromucosal spray that contains THC and cannabidiol (CBD). It was issued a marketing authorisation by the MHRA, for treatment of spasticity in people with multiple sclerosis who have failed to respond adequately to other anti-spasticity medications, on 16 June 2010. In October 2014, the National Institute for Health and Care Excellence recommended that Sativex is not offered for use on the NHS because it is not a cost-effective treatment. Sativex therefore is not routinely prescribed on the NHS, and can only be prescribed for an individual patient, where local governance and funding arrangements allow for this.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 251364 question first answered 13/05/2019 15:38:24 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4425 label Biography information for Jo Stevens

1121479

	registered interest
	date	11/04/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many NHS prescriptions for medicinal cannabis (a) THC and (b) CBD have been issued in England since December 2018.
	tabling member constituency	Cardiff Central
	tabling member printed	Jo Stevens
	uin	244142
	answer	answer is ministerial correction date of answer 24/04/2019 answer text <p>NHS England is using extant systems to monitor use of the newly rescheduled unlicensed cannabis-based products for medicinal use in England. In England, these systems monitor the number of items dispensed and associated costs in primary care and the volume of products used and associated cost in secondary care. NHS England Controlled Drug Accountable Officers are also collecting local intelligence in both the National Health Service and independent sector.</p><p>Data on the number of items of cannabis-based medicines dispensed in NHS primary care in England from December 2018 to January 2019 has been published by the NHS Business Services Authority. Such data is published three months in arrears, and we expect information for February 2019 to be published shortly.</p><p>The published data shows that the following number of items of Nabilone and Sativex (two cannabis-based medicines) were dispensed from December 2018 to January 2019:</p><table><tbody><tr><td><p> </p></td><td><p>December 2018</p></td><td><p>January 2019</p></td></tr><tr><td><p>Nabilone</p></td><td><p>49</p></td><td><p>44</p></td></tr><tr><td><p>Sativex</p></td><td><p>181</p></td><td><p>167</p></td></tr></tbody></table><p><strong> </strong></p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 24/04/2019 13:15:40 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4425 label Biography information for Jo Stevens